A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

Ovarian cancers are often found when they are already advanced and hard to treat. Researchers have long believed this was because women first experienced symptoms when ovarian cancer was already ...

Experts say ovarian cancer causes more deaths than all other female reproduction system cancers and is difficult to diagnose ...

Vintafolide is a novel folate receptor (FR)-targeted agent that has demonstrated clinical activity and a good toxicity profile in patients with ovarian cancer and adenocarcinoma of the lung.

These findings could lead to personalized therapies that target the right patients at the right time, offering hope for improving care for ovarian cancer—a highly aggressive and common malignancy.

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...

A new international study shows that AI-based models can outperform human experts at identifying ovarian cancer in ultrasound images.

Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

The Minnesota Department of Health (MDH) says about 3,850 women in Minnesota are living with an ovarian cancer diagnosis and ...

BTIG raised the firm’s price target on Verastem (VSTM) to $20 from $13 and keeps a Buy rating on the shares after the company announced the FDA ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...